Open main menu

Psychiatrienet β

Difference between revisions of "Agomelatine-sertraline"

 
(One intermediate revision by the same user not shown)
Line 4: Line 4:
 
| stop = {{StopAgomelatine}}
 
| stop = {{StopAgomelatine}}
 
| start =  
 
| start =  
 +
{{startSertraline}}
 +
| info =
 
* A wash-out period is not necessary.
 
* A wash-out period is not necessary.
* Start administration of sertraline the next day in a dosage of 25 mg/day.
 
* If necessary, increase dosage of sertraline.
 
 
 
}}
 
}}

Latest revision as of 08:17, 14 October 2015

Agomelatine
Type Antidepressant
Group other
links
ATC-code N06AX22
EMEA valdoxan
PubChem 82148
PubMed Agomelatine
Kompas (Dutch) Agomelatine
Wikipedia Agomelatine
Sertraline
Type Antidepressant
Group SSRI
links
Medscape Sertraline
PubChem 68617
PubMed Sertraline
Kompas (Dutch) Sertraline
Wikipedia Sertraline

Switch medication from agomelatine to sertraline.[1] [2]

Nietinrijdenbord.png Stop agomelatine
  • Day 1: Stop agomelatine.
  • Agomelatine can be stopped abruptly for every dosage.[3]
Eenrichtingbord.png Start sertraline
  • Day 2: Start sertraline in the dosage of 25 mg/day.
  • After 3 weeks: If necessary increase dosage gradually to 50-200 mg/day
Infobord.png More information
  • A wash-out period is not necessary.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  3. McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.